


Corres. and Mail  
**RECEIVED BOX AF**

AF  
1617

JUL 1 2002

TECH CENTER 1600/2900  
RESPONSE UNDER 37 C.F.R. § 1.116  
EXPEDITED PROCEDURE  
GROUP 1617  
PATENT APPLICATION



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

#10  
HKO  
7-5-02

In re application of

Docket No: Q64929

Shohei TANAKA, et al.

Appln. No.: 09/869,122

Group Art Unit: 1617

Confirmation No.: 2326

Examiner: Hui, S.

Filed: June 25, 2001

For: PHARMACEUTICAL COMPOSITIONS FOR TREATING BONE LESIONS IN  
MULTIPLE MYELOMA

**RESPONSE UNDER 37 C.F.R. § 1.116**

ATTN: BOX AF  
Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Office Action dated March 27, 2002, please consider the remarks as submitted herewith.

**REMARKS**

Claims 7 and 9-13 are all the claims pending in the application. Each of the claims has been rejected.

**I. Rejection of claims under 35 U.S.C. § 103**

At pages 2-4 of the Office Action, claims 7 and 9-13 are rejected under 35 U.S.C. §103(a) over Isomura et al. (US 4,990,503) in view of Shipman et al. (*Leukemia and Lymphoma*, 1998).

✱